References
1. Ostrom Q, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-oncology. 2014:iv1-63.
2. Ljubimov V, Ramesh A, Davani S, Danielpour M, Breunig J, Black K. Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. Advanced drug delivery reviews. 2022;181:114033.
3. Rivoirard R, Vallard A, Langrand-Escure J, Ben Mrad M, Wang G, Guy J, et al. Thirty years of phase I radiochemotherapy trials: Latest development. European journal of cancer (Oxford, England : 1990). 2016;58:1-7.
4. Sun G, Rong D, Li Z, Sun G, Wu F, Li X, et al. Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges. Frontiers in cell and developmental biology. 2021;9:694363.
5. Lin X, DeAngelis LM. Treatment of Brain Metastases. J Clin Oncol. 2015;33(30):3475-84.
6. Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20(1):26-41.
7. Kirson E, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, et al. Disruption of cancer cell replication by alternating electric fields. Cancer research. 2004;64(9):3288-95.
8. Stupp R, Wong E, Kanner A, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. European journal of cancer (Oxford, England : 1990). 2012;48(14):2192-202.
9. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017;318(23):2306-16.
10. Kutuk T, Appel H, Avendano M, Albrecht F, Kaywin P, Ramos S, et al. Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data. Cancers. 2022;14(8).
11. Robinson AJ, Jain A, Sherman HG, Hague RJM, Rahman R, Sanjuan-Alberte P, et al. Toward Hijacking Bioelectricity in Cancer to Develop New Bioelectronic Medicine. Advanced Therapeutics. 2021;4(3):2000248.
12. Levin M, Stevenson CG. Regulation of Cell Behavior and Tissue Patterning by Bioelectrical Signals: Challenges and Opportunities for Biomedical Engineering. Annual Review of Biomedical Engineering. 2012;14(1):295-323.
13. Davies A, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy of Sciences. 2013;1291:86-95.
14. Xu S, Luo C, Chen D, Tang L, Chen L, Liu Z. Whole transcriptome and proteome analyses identify potential targets and mechanisms underlying tumor treating fields against glioblastoma. Cell Death Dis. 2022;13(8):721.
15. Gutin P, Wong E. Noninvasive application of alternating electric fields in glioblastoma: a fourth cancer treatment modality. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting. 2012:126-31.
16. Kline-Smith S, Walczak C. Mitotic spindle assembly and chromosome segregation: refocusing on microtubule dynamics. Molecular cell. 2004;15(3):317-27.
17. Barreca M, Stathis A, Barraja P, Bertoni F. An overview on anti-tubulin agents for the treatment of lymphoma patients. Pharmacology & therapeutics. 2020;211:107552.
18. Voloshin T, Schneiderman R, Volodin A, Shamir R, Kaynan N, Zeevi E, et al. Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility through Regulation of Microtubule and Acting Dynamics. Cancers. 2020;12(10).
19. Tooley A, Gilden J, Jacobelli J, Beemiller P, Trimble W, Kinoshita M, et al. Amoeboid T lymphocytes require the septin cytoskeleton for cortical integrity and persistent motility. Nature cell biology. 2009;11(1):17-26.
20. Gilden J, Peck S, Chen Y, Krummel M. The septin cytoskeleton facilitates membrane retraction during motility and blebbing. The Journal of cell biology. 2012;196(1):103-14.
21. Kirson E, Dbalý V, Tovarys F, Vymazal J, Soustiel J, Itzhaki A, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(24):10152-7.
22. Giladi M, Schneiderman R, Voloshin T, Porat Y, Munster M, Blat R, et al. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells. Scientific reports. 2015;5:18046.
23. Gera N, Yang A, Holtzman T, Lee S, Wong E, Swanson K. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PloS one. 2015;10(5):e0125269.
24. Lee SX, Wong ET, Swanson KD. MITOSIS INTERFERENCE OF CANCER CELLS DURING ANAPHASE BY ELECTRIC FIELD FROM NOVOTTF-100A. NEURO-ONCOLOGY. 2011;13:13-4.
25. Kim E, Kim Y, Song H, Jeong Y, Lee J, Sung J, et al. Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation. Oncotarget. 2016;7(38):62267-79.
26. Giladi M, Munster M, Schneiderman R, Voloshin T, Porat Y, Blat R, et al. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. Radiation oncology (London, England). 2017;12(1):206.
27. Karanam N, Srinivasan K, Ding L, Sishc B, Saha D, Story M. Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines. Cell death & disease. 2017;8(3):e2711.
28. Zhao W, Steinfeld J, Liang F, Chen X, Maranon D, Jian Ma C, et al. BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing. Nature. 2017;550(7676):360-5.
29. Kais Z, Rondinelli B, Holmes A, O’Leary C, Kozono D, D’Andrea A, et al. FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair. Cell reports. 2016;15(11):2488-99.
30. Karanam N, Ding L, Aroumougame A, Story M. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy. Translational research : the journal of laboratory and clinical medicine. 2020;217:33-46.
31. Kirson E, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman R, et al. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clinical & experimental metastasis. 2009;26(7):633-40.
32. Shi P, Tian J, Ulm B, Mallinger J, Khoshbouei H, Deleyrolle L, et al. Tumor Treating Fields Suppression of Ciliogenesis Enhances Temozolomide Toxicity. Frontiers in oncology. 2022;12:837589.
33. Kalluri R, Weinberg R. The basics of epithelial-mesenchymal transition. The Journal of clinical investigation. 2009;119(6):1420-8.
34. Kim E, Song H, Yoo S, Yoon M. Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis. Oncotarget. 2016;7(40):65125-36.
35. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature reviews Cancer. 2002;2(3):161-74.
36. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vascular health and risk management. 2006;2(3):213-9.
37. Inoue T, Nakayama Y, Li Y, Matsumori H, Takahashi H, Kojima H, et al. SIRT2 knockdown increases basal autophagy and prevents postslippage death by abnormally prolonging the mitotic arrest that is induced by microtubule inhibitors. The FEBS journal. 2014;281(11):2623-37.
38. Silginer M, Weller M, Stupp R, Roth P. Biological activity of tumor-treating fields in preclinical glioma models. Cell death & disease. 2017;8(4):e2753.
39. Kim E, Jo Y, Sai S, Park M, Kim J, Kim J, et al. Tumor-treating fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma cells. Oncogene. 2019;38(39):6630-46.
40. Holdgaard S, Cianfanelli V, Pupo E, Lambrughi M, Lubas M, Nielsen J, et al. Selective autophagy maintains centrosome integrity and accurate mitosis by turnover of centriolar satellites. Nature communications. 2019;10(1):4176.
41. Tsujimoto Y, Shimizu S. Another way to die: autophagic programmed cell death. Cell Death & Differentiation. 2005;12(2):1528-34.
42. Shteingauz A, Porat Y, Voloshin T, Schneiderman R, Munster M, Zeevi E, et al. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields). Cell death & disease. 2018;9(11):1074.
43. Wong E, Lok E, Gautam S, Swanson K. Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. British journal of cancer. 2015;113(2):232-41.
44. Voloshin T, Kaynan N, Davidi S, Porat Y, Shteingauz A, Schneiderman R, et al. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer immunology, immunotherapy : CII. 2020;69(7):1191-204.
45. Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala A, Shen S, et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell death and differentiation. 2014;21(1):79-91.
46. Park J, Song K, Jung S, Ahn J, Hwang S, Kim J, et al. Tumor-Treating Fields Induce RAW264.7 Macrophage Activation Via NK-κB/MAPK Signaling Pathways. Technology in cancer research & treatment. 2019;18:1533033819868225.
47. Chen D, Le S, Hutchinson T, Calinescu A, Sebastian M, Jin D, et al. Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma. The Journal of clinical investigation. 2022.
48. Aguilar AA, Ho MC, Chang E, Carlson KW, Natarajan A, Marciano T, et al. Permeabilizing Cell Membranes with Electric Fields. Cancers (Basel). 2021;13(9).
49. Chang E, Patel C, Pohling C, Young C, Song J, Flores T, et al. Tumor treating fields increases membrane permeability in glioblastoma cells. Cell death discovery. 2018;4:113.
50. Probst U, Fuhrmann I, Beyer L, Wiggermann P. Electrochemotherapy as a New Modality in Interventional Oncology: A Review. Technology in cancer research & treatment. 2018;17:1533033818785329.
51. Neuhaus E, Zirjacks L, Ganser K, Klumpp L, Schüler U, Zips D, et al. Alternating Electric Fields (TTFields) Activate Ca1.2 Channels in Human Glioblastoma Cells. Cancers. 2019;11(1).
52. Chinigò G, Castel H, Chever O, Gkika D. TRP Channels in Brain Tumors. Front Cell Dev Biol. 2021;9:617801.
53. Li X, Yang F, Rubinsky B. A Theoretical Study on the Biophysical Mechanisms by Which Tumor Treating Fields Affect Tumor Cells During Mitosis. IEEE transactions on bio-medical engineering. 2020;67(9):2594-602.
54. Kessler AF, Salvador E, Domrose D, Burek M, Schaeffer C, Brami CT, et al. Blood Brain Barrier (BBB) Integrity Is Affected By Tumor Treating Fields (TTFields) in Vitro and In Vivo. International Journal of Radiation Oncology Biology Physics. 2019;105(1):S162-S3.
55. Ceresoli G, Aerts J, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck J, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. The Lancet Oncology. 2019;20(12):1702-9.
56. Giladi M, Schneiderman R, Porat Y, Munster M, Itzhaki A, Mordechovich D, et al. Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields. Pancreatology : official journal of the International Association of Pancreatology (IAP) [et al]. 2014;14(1):54-63.
57. Akbarnejad Z, Eskandary H, Dini L, Vergallo C, Nematollahi-Mahani S, Farsinejad A, et al. Cytotoxicity of temozolomide on human glioblastoma cells is enhanced by the concomitant exposure to an extremely low-frequency electromagnetic field (100Hz, 100G). Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2017;92:254-64.
58. Branter J, Estevez-Cebrero M, Diksin M, Griffin M, Castellanos-Uribe M, May S, et al. Genome-Wide Expression and Anti-Proliferative Effects of Electric Field Therapy on Pediatric and Adult Brain Tumors. International journal of molecular sciences. 2022;23(4).
59. Kirson ED, Wasserman Y, Izhaki A, Mordechovich D, Gurvich Z, Dbaly V, et al. Modeling tumor growth kinetics and its implications for TTFields treatment planning. Neuro-Oncology. 2010:48-.
60. Norden A, Young G, Setayesh K, Muzikansky A, Klufas R, Ross G, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779-87.
61. Iwamoto F, Abrey L, Beal K, Gutin P, Rosenblum M, Reuter V, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology. 2009;73(15):1200-6.
62. Rosen J, Blau T, Grau S, Barbe M, Fink G, Galldiks N. Extracranial Metastases of a Cerebral Glioblastoma: A Case Report and Review of the Literature. Case reports in oncology. 2018;11(2):591-600.
63. Korshoej A, Lukacova S, Lassen-Ramshad Y, Rahbek C, Severinsen K, Guldberg T, et al. OptimalTTF-1: Enhancing tumor treating fields therapy with skull remodeling surgery. A clinical phase I trial in adult recurrent glioblastoma. Neuro-oncology advances. 2020;2(1):vdaa121.
64. Mikic N, Poulsen F, Kristoffersen K, Laursen R, Guldberg T, Skjøth-Rasmussen J, et al. Study protocol for OptimalTTF-2: enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial. BMC cancer. 2021;21(1):1010.
65. Fisher J, Adamson D. Current FDA-Approved Therapies for High-Grade Malignant Gliomas. Biomedicines. 2021;9(3).
66. Lazaridis L, Schäfer N, Teuber-Hanselmann S, Blau T, Schmidt T, Oster C, et al. Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. Journal of cancer research and clinical oncology. 2020;146(3):787-92.
67. Bokstein F, Blumenthal D, Limon D, Harosh C, Ram Z, Grossman R. Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study. Frontiers in oncology. 2020;10:411.
68. Miller R, Song A, Ali A, Niazi M, Bar-Ad V, Martinez N, et al. Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma. Frontiers in oncology. 2022;12:896246.
69. Lin Y, Chen B. Case report: tumor-treating fields prolongs IDH-mutant anaplastic astrocytoma progression-free survival and pathological evolution to glioblastoma. Annals of translational medicine. 2021;9(24):1804.
70. Majores M, von Lehe M, Fassunke J, Schramm J, Becker AJ, Simon M. Tumor recurrence and malignant progression of gangliogliomas. Cancer. 2008;113(12):3355-63.
71. Meletath S, Pavlick D, Brennan T, Hamilton R, Chmielecki J, Elvin J, et al. Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma. Journal of the National Comprehensive Cancer Network : JNCCN. 2016;14(11):1345-50.
72. Achrol A, Rennert R, Anders C, Soffietti R, Ahluwalia M, Nayak L, et al. Brain metastases. Nature reviews Disease primers. 2019;5(1):5.
73. Kirschenbaum D, Amit I. Brain metastases: Not all tumors are created equal. Neuron. 2022;110(7):1097-9.
74. Mehta M, Gondi V, Ahluwalia M, Brown P. Radiosurgery followed by tumour treating fields (TTFields) for brain metastases (1-10) from NSCLC in the phase III METIS trial. Annals of Oncology. 2019;30.
75. Wu H, Yang L, Liu H, Zhou D, Chen D, Zheng X, et al. Exploring the efficacy of tumor electric field therapy against glioblastoma: An in vivo and in vitro study. CNS neuroscience & therapeutics. 2021;27(12):1587-604.
76. Elzinga G, Wong E. Resolution of cystic enhancement to add-on tumor treating electric fields for recurrent glioblastoma after incomplete response to bevacizumab. Case reports in neurology. 2014;6(1):109-15.
77. Lu G, Rao M, Zhu P, Liang B, El-Nazer R, Fonkem E, et al. Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study. Frontiers in neurology. 2019;10:42.
78. Den R, Kamrava M, Sheng Z, Werner-Wasik M, Dougherty E, Marinucchi M, et al. A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. International journal of radiation oncology, biology, physics. 2013;85(2):321-8.
79. Jo Y, Kim E, Sai S, Kim J, Cho J, Kim H, et al. Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy. International journal of molecular sciences. 2018;19(11).
80. Kessler A, Frömbling G, Gross F, Hahn M, Dzokou W, Ernestus R, et al. Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition. Cell death discovery. 2018;4:12.
81. Jo Y, Han Y, Lee E, Seo J, Oh G, Sung H, et al. The combination of tumor treating fields and hyperthermia has synergistic therapeutic effects in glioblastoma cells by downregulating STAT3. American journal of cancer research. 2022;12(3):1423-32.
82. Lee J, Grabowski M, Lathia J. Tumor Treating Fields: killing two birds with one stone. The Journal of clinical investigation. 2022;132(8).
83. Wen P, Macdonald D, Reardon D, Cloughesy T, Sorensen A, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(11):1963-72.
84. Jackson E, Barboriak D, Bidaut L, Meyer C. Magnetic resonance assessment of response to therapy: tumor change measurement, truth data and error sources. Translational oncology. 2009;2(4):211-5.
85. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent M. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. The Lancet Oncology. 2008;9(5):453-61.
86. Mohan S, Chawla S, Wang S, Verma G, Skolnik A, Brem S, et al. Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience. CNS oncology. 2016;5(3):137-44.
87. Tian M, He X, Jin C, He X, Wu S, Zhou R, et al. Transpathology: molecular imaging-based pathology. Eur J Nucl Med Mol Imaging. 2021;48(8):2338-50.
88. Werner J, Lohmann P, Fink G, Langen K, Galldiks N. Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors. Molecules (Basel, Switzerland). 2020;25(6).
89. Langen K, Watts C. Neuro-oncology: Amino acid PET for brain tumours - ready for the clinic? Nature reviews Neurology. 2016;12(7):375-6.
90. Singhal T, Narayanan T, Jain V, Mukherjee J, Mantil J. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Molecular imaging and biology. 2008;10(1):1-18.
91. Ceccon G, Lazaridis L, Stoffels G, Rapp M, Weber M, Blau T, et al. Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. European journal of nuclear medicine and molecular imaging. 2018;45(9):1626-35.
92. Bosnyák E, Barger G, Michelhaugh S, Robinette N, Amit-Yousif A, Mittal S, et al. Amino Acid PET Imaging of the Early Metabolic Response During Tumor-Treating Fields (TTFields) Therapy in Recurrent Glioblastoma. Clinical nuclear medicine. 2018;43(3):176-9.
93. Witney T, James M, Shen B, Chang E, Pohling C, Arksey N, et al. PET imaging of tumor glycolysis downstream of hexokinase through noninvasive measurement of pyruvate kinase M2. Science translational medicine. 2015;7(310):310ra169.
94. Christofk H, Vander Heiden M, Harris M, Ramanathan A, Gerszten R, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452(7184):230-3.
95. Patel C, Beinat C, Xie Y, Chang E, Gambhir S. Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression. Neoplasia (New York, NY). 2021;23(1):58-67.
96. DeBerardinis R, Chandel N. We need to talk about the Warburg effect. Nature metabolism. 2020;2(2):127-9.
97. Xu K, Yin N, Peng M, Stamatiades E, Chhangawala S, Shyu A, et al. Glycolytic ATP fuels phosphoinositide 3-kinase signaling to support effector T helper 17 cell responses. Immunity. 2021;54(5):976-87.e7.
98. Taphoorn M, Dirven L, Kanner A, Lavy-Shahaf G, Weinberg U, Taillibert S, et al. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA oncology. 2018;4(4):495-504.
99. Lacouture M, Davis M, Elzinga G, Butowski N, Tran D, Villano J, et al. Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. Seminars in oncology. 2014:S1-14.
100. Toms S, Kim C, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. Journal of neuro-oncology. 2019;141(2):467-73.
101. Gatson N, Barnholtz-Sloan J, Drappatz J, Henriksson R, Hottinger A, Hinoul P, et al. Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. Frontiers in oncology. 2021;11:679702.
102. Green A, Mulcahy Levy J, Vibhakar R, Hemenway M, Madden J, Foreman N, et al. Tumor treating fields in pediatric high-grade glioma. Child’s nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. 2017;33(7):1043-5.
103. Wenger C, Miranda P, Salvador R, Thielscher A, Bomzon Z, Giladi M, et al. A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling. IEEE reviews in biomedical engineering. 2018;11:195-207.
104. Mehta M, Wen P, Nishikawa R, Reardon D, Peters K. Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Critical reviews in oncology/hematology. 2017;111:60-5.
105. Vergote I, von Moos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C. Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. Gynecologic oncology. 2018;150(3):471-7.
106. Wick W. TTFields: where does all the skepticism come from? Neuro-oncology. 2016;18(3):303-5.
107. Burri S, Gondi V, Brown P, Mehta M. The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists. American journal of clinical oncology. 2018;41(2):191-6.
108. Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro-oncology. 2016;18(8):1129-36.
109. Haj A, Doenitz C, Hohenberger C, Brawanski A, Proescholdt MA. P01.144 TTFields for newly diagnosed Glioblastoma: Impact of consultation strategy. (1522-8517 (Print)).
110. Salzberg M, Kirson E, Palti Y, Rochlitz C. A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors. Onkologie. 2008;31(7):362-5.